The FDA granted approval to Altuviiio as a first-in-class, high-sustained factor VIII replacement therapy for hemophilia A patients on February 22, 2023.
The FDA granted accelerated approval to Sparsentan for its ability to reduce proteinuria (excess protein in the urine) in adults with primary immunoglobulin A nephropathy.
Elacestrant was approved by the FDA on January 27, 2023, for the treatment of advanced or metastatic breast cancer in postmenopausal women and adult men.
Ublituximab, marketed under the brand name Briumvi, is a CD20 monoclonal antibody used in the treatment of multiple sclerosis (MS). Ublituximab was approved by the FDA on December 28, 2022.
Xenoview received FDA approval on December 23, 2022. It plays a crucial role in providing clearer images of certain areas of the body, particularly the lungs, without the need for radiation exposure.